STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Cardio Diagnostics Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Wendy J. Betts reported acquiring 1,559 stock options of Cardio Diagnostics Holdings, Inc. (CDIO) on 09/30/2025. The options have an exercise price of $4.01, are exercisable immediately (09/30/2025) and expire on 09/30/2035. The filing shows these options cover 1,559 underlying shares, and following the reported transaction Ms. Betts beneficially owns 4,002 shares of common stock. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025. The report is a Section 16 disclosure of insider changes in beneficial ownership and contains no additional financial results or contractual terms beyond the option details.

Positive
  • Director acquisition: 1,559 options acquired at $4.01 shows insider participation
  • Immediate exercisability: Options exercisable on 09/30/2025, providing clear vesting/exercise status
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Betts Wendy J

(Last) (First) (Middle)
C/O CARDIO DIAGNOSTICS HOLDINGS INC.
311 W. SUPERIOR ST. SUITE 444

(Street)
CHICAGO IL 60654

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $4.01 09/30/2025 A 1,559 09/30/2025 09/30/2035 Common Stock 1,559 $4.01 4,002 D
Explanation of Responses:
/s/ Elisa Luqman as attorney-in-fact for Wendy Betts 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Cardio Diagnostics (CDIO) director Wendy Betts report?

She reported acquiring 1,559 stock options on 09/30/2025 with an exercise price of $4.01.

How many shares does Wendy Betts beneficially own after the reported transaction?

The Form 4 shows she beneficially owns 4,002 shares following the transaction.

When do the options become exercisable and when do they expire?

The options are exercisable on 09/30/2025 and expire on 09/30/2035.

Who signed the Form 4 and when was it signed?

The Form 4 was signed by Elisa Luqman as attorney-in-fact for Wendy Betts on 10/03/2025.

What is the reporting person’s relationship to CDIO?

The filing identifies Wendy J. Betts as a Director of Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings Inc

NASDAQ:CDIO

CDIO Rankings

CDIO Latest News

CDIO Latest SEC Filings

CDIO Stock Data

4.53M
1.70M
7.16%
4.81%
0.98%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CHICAGO